You don’t have permission to access “http://www.moneycontrol.com/world/trump-promised-a-us-manufacturing-boom-why-the-revival-has-yet-to-materialise-article-13942264.html” on this server.
Reference #18.e5ab3717.1780871572.3c5cfe38
https://errors.edgesuite.net/18.e5ab3717.1780871572.3c5cfe38
Conservative Leader Pierre Poilievre unveiled the party’s most substantial auto strategy to date under his leadership, which he says will both bring back production to Canada and be “highly attractive” to partners south of the border.
“Canada’s auto sector must stay alive and it must have access to the U.S. to do so,” Poilievre said while in Windsor, Ont., on Sunday.
Poilievre said he’d like to institute a tariff-free auto pact and has a plan to restore Canada’s auto production to two million cars per year over the next 10 years.
Also included in the plan is a call to remove the GST on all Canadian-made vehicles, something the NDP and Conservatives proposed during the 2025 general election campaign.
The proposal was announced amid Poilievre’s first visit to the United States since U.S. President Donald Trump launched his trade war, a significant marker in the Conservative leader’s shifting focus on global trade pressures brought about by the Trump administration.
“He’s going down there to sell Canada, it’s what we have to do,” Conservative labour critic Kyle Seeback told Rosemary Barton Live.
Seeback said the purpose of the trip is not to give the impression that there are two prime ministers in Canada.
Rather, he said, with the CUSMA (Canada-U.S.-Mexico Agreement) review coming up, Poilievre is making the case to U.S. business leaders about the importance of the trading relationship and how tariffs can hurt both countries.
WATCH | Conservative labour critic on the party’s auto plan, Poilievre’s U.S. trip:
Federal Conservatives pitch new auto strategy as tariffs roil industry
Conservative Leader Pierre Poilievre has announced a plan for the hard-hit auto sector that aims to secure tariff-free access to the U.S. market and boost Canada’s auto production. Chief political correspondent Rosemary Barton speaks with Conservative MP Kyle Seeback, the party’s labour critic, about the plan, as well as Poilievre’s U.S. trip.
At the heart of this auto strategy is the push to get Trump to drop tariffs on Canada by selling this strategy as a better way to restore U.S. manufacturing.
This push rests on the assumption that Trump is open to solving its trade relationship with Canada, despite there being a lack of evidence to suggest willingness on the part of the administration.
Asked how he’d get Trump to give the green light, Poilievre says his plan addresses the president’s desire to repatriate production to the U.S. and would see a “massive production gain” on both sides of the border.
Poilievre meets with workers and politicians at Cavalier Tool and Manufacturing in Windsor, Ont., on Sunday. (Pratyush Dayal/CBC)
Poilievre laid out a one-for-one deal, where for every car manufactured in Canada, he said, that same producer would get a car to sell duty free from a partner in CUSMA.
This can be sold as a “win, win,” said Seeback.
“It’s a better way for the United States to reshore the auto manufacturing in their country while preserving their best export market for autos, which is Canada.”
Seeback says this strategy harkens back to the 1965 auto pact that kick-started free trade between Canada and the U.S., prior to the North American Free Trade Agreement.
Seeback said this new version of the auto pact would position Canada to be able to harmonize with the U.S. on Chinese electric vehicle policy, part of Poilievre’s strategy to bring “maximum leverage” to the CUSMA review.
“When you put these things together, helping them restore their auto manufacturing, preserving the Canadian market and better alignment on things like Chinese electric vehicles, we actually think there’s an opportunity to get that deal,” said Seeback.
The federal government recently struck a deal with China to bring tariff relief for Canada’s agricultural and seafood sectors.
In a move that broke ranks with the U.S., Prime Minister Mark Carney agreed to allow up to 49,000 Chinese electric vehicles into Canada, lowering a 100 per cent tariff on imports, imposed in 2024, back to six per cent.
The U.S. strategy has been focused on protecting its big three automakers: General Motors, Ford Motor Company and Stellantis.
To thwart Trump’s protectionist policies, Carney’s approach has been to diversify Canada’s trading partners and look to attract European, Japanese and Korean automakers to Canada.
Now, more than a year after Trump returned to office, Poilievre is looking to show his plan for dealing with the White House.
For decades, Canada’s sales pitch to the world has rested on having tariff-free access to the U.S. market. Seeback said that if that’s not the case, there’s “not a single producer in the world” that will come to Canada to start new production.
Seeback calls Carney’s approach “managed decline” and said he does not believe it will work.
Poilievre said that even Mexico would have to accept the plan to avoid ending up with something “much worse.”
On Friday, Poilievre was in Detroit to meet with senior executives of General Motors and Ford. He crossed the Detroit River back into Canada Sunday to make his auto strategy announcement in Windsor.
His U.S. travel will continue with stops in Texas and New York, with no visit planned for the U.S. capital.
In an interview on The Paul Wells Show podcast, Poilievre said he updated Carney about his travel plans on the margins on Question Period last Wednesday and plans to debrief him once he returns.
According to market insights firms SPINS, U.S. cognitive health vitamin, mineral and supplement sales reached approximately $499 million over the latest 52-week period, with unit sales exceeding 19.5 million. While the category remains one of the industry’s largest condition-specific segments, dollar sales declined slightly year over year, underscoring the difficulty of sustaining growth in a mature market.
Within that landscape, CHEMI Nutra says expanded U.S. manufacturing access to its choline-rich Alpha-GPC ingredients is enabling shorter formulation timelines while preserving Italian pharma-level purity and stability. CHEMI Nutra, incorporated in 2001, manufacturers Alphasize at CHEMI S.p.A.’s pharmaceutical-grade facilities in Milan and Patrica, Italy.
Alpha-GPC (Alpha-glycerylphosphorylcholine) is used across a wide range of cognitive health products, particularly in blended formulations positioned for focus, memory and mental performance. Its use, however, has largely remained concentrated in powders and capsules.
Mike Petteruti, president & general manager of CHEMI Nutra highlighted that delivery format innovation continues to shape future development strategies for choline ingredients.
“Future development will focus on delivery systems that improve bioavailability, format flexibility and consumer compliance, including liquids, softgels and hybrid systems,” he told NutraIngredients. “The biggest opportunity lies in integrating choline solutions into multi-benefit formulations without compromising stability or sensory experience.”
Efforts to expand Alpha-GPC into liquid and softgel formats have historically faced stability challenges, and the “main barriers were limited access to suitable liquid Alpha-GPC and a lack of confidence and know-how around softgel applications,” according to Petteruti.
“Alpha-GPC’s sensitivity to moisture and interaction with lipid systems made long-term stability difficult without system-level expertise,” he noted.
Those issues have limited how quickly brands could pursue alternative delivery formats, but Petteruti said those challenges can now be addressed via CHEMI Nutra’s AlphaSize Liquid-Science Platform.
Introduced in 2025, this platform allows for the use of “Liquid 85L” Alpha-GPC in applications such as shots, ready-to-drink (RTD) beverages, gummies, drops and softgels, while maintaining the stability and efficacy of the ingredient.
Moving forward, Petteruti added, regulatory clarity and scientific substantiation will continue to influence how quickly new formats reach the market.
As competition heats up, regulatory positioning is also playing a more substantial role in ingredient selection. Alphasize is the only New Dietary Ingredient (NDI)-cleared Alpha-GPC in the U.S. market.
“Expanded U.S. manufacturing access to an NDI-supported Alpha-GPC increases regulatory confidence and commercial clarity for brands,” Petteruti said. “NDI support provides a well-documented safety and quality foundation, while domestic production improves traceability, continuity and alignment with FDA expectations.”
He added that those factors shorten supply chains and allow brands to plan innovation cycles with greater certainty in cognitive health and brain-mood formulations.
US-based manufacturing is also becoming more closely tied to transparency and documentation expectations.
“The AlphaSize Liquid-Science platform combines U.S.-based manufacturing with the same transparency and quality standards applied across CHEMI Nutra’s global operations,” Petteruti said. “Domestic production enables clearer documentation, tighter quality oversight and closer collaboration around formulation, stability and delivery formats.”
On-shoring can also make technical or regulatory decision-making processes less complex, as it “provides more direct access to this know-how and more consistent answers around regulatory confidence and performance expectations,” he added.
Voluntary agreement will allow millions of Americans to purchase medicines at significantly discounted rates
Agreement provides Johnson & Johnson pharmaceutical products an exemption from U.S. tariffs
Company announces two new additional manufacturing facilities to be built in North Carolina and Pennsylvania; continues to deliver on $55 billion U.S. investment
NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, today announced a voluntary agreement with the Trump Administration to improve access to medicines and lower costs for millions of American patients. The joint agreement meets the requests laid out by President Trump to the industry and provides the Company’s pharmaceutical products an exemption from tariffs1.
“Today’s agreement shows that when the public and private sectors work together towards shared goals, we can deliver real results for patients and the U.S. economy,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “I’m proud that Johnson & Johnson is answering President Trump’s call to lower drug prices for everyday Americans while maintaining our role in improving and saving lives and ensuring that the United States continues to lead the world in healthcare innovation.”
Improving Access and Lowering Costs for U.S. Patients
Johnson & Johnson is working with the Trump Administration to improve access to medicines and lower costs for millions of American patients. The Company is:
Delivering On Our $55B U.S. Investment
Johnson & Johnson also continues to deliver on our previously announced $55 billion investment to support U.S. manufacturing, research and development, and technology investments by early 2029. In just the last 10 months, the Company has initiated billions of dollars in investment in U.S. manufacturing, which will support the Company’s goal of manufacturing the vast majority of its advanced medicines in the U.S. to meet the needs of U.S. patients.
Today, as part of the $55 billion investment, the Company is announcing two new U.S. manufacturing facilities, including a next generation cell therapy manufacturing site in Pennsylvania and a state-of-the-art drug product manufacturing facility in North Carolina.
Additionally, construction is progressing on our $2 billion state-of-the-art biologics manufacturing facility in Wilson, North Carolina, which the Company broke ground on last year. That project will create approximately 5,000 skilled manufacturing and construction jobs in the state. Johnson & Johnson is already ramping up the hiring of advanced manufacturing employees to work at the facility.
In September, the Company also secured a new 160,000+ square foot dedicated biopharmaceutical manufacturing site in Holly Springs, North Carolina. The $2 billion commitment over the next 10 years will create approximately 120 new jobs in North Carolina.
Johnson & Johnson expects to announce additional U.S. investments later this year.
About Johnson & Johnson:
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more at www.jnj.com.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory actions; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
1 Specific terms of the agreement remain confidential.
Contacts
Media contact:
media-relations@its.jnj.com
Investor contact:
investor-relations@its.jnj.com
